The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) decreased by -$0.11 on Friday to finish at $14.74, down -0.74 percent. The last five days have seen an average of 1,230,880 shares of common stock traded. 24 times new highs were reached in the current year, with a gain of $4.10. The average number of shares traded over the last 20 days was 2,061,655, while the average volume over the last 50 days totaled 1,907,220.
DVAX stock appreciated 4.76% since last month. On 08/02/23, the company’s shares reached a one-month low of $13.30. The stock touched a high of $15.12 on 08/08/23, after rallying from a low of $9.42 in 52 weeks. The price of DVAX stock has risen by 38.53% or $4.10 this year, reaching a new high 24 times. Still, the stock price is down -2.51% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DVAX stock investors should be aware that Dynavax Technologies Corporation (DVAX) stock had its last reported insider trading activity 4 days ago on Aug 24. On Aug 24, SVP and CMO Janssen Robert sold 600 shares at $15.02 each. This transaction resulted in the insider making $9,012. On Aug 23, Janssen Robert sold 34,857 shares at a price of US$15.01. After the transaction, the insider now owns 49,925 shares. Director Hack Andrew A. F. had earlier sold 1,500,000 shares on Aug 08 for $14.39 a share. The transaction was completed for $21,585,000.
Valuation Metrics
Dynavax Technologies Corporation (DVAX) has a trailing price-to-earnings (P/E) ratio of 21.15. Beta for the stock is 1.49. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.16, the price-to-book (PB) ratio of 3.28, and the price-to-cash flow ratio of 12.98.
Financial Health
For the three months ended June 29, Dynavax Technologies Corporation’s quick ratio was 16.60, while its current ratio was 17.80, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.38, and the total debt to equity ratio is 0.38. As far as profitability goes, gross margin for the trailing twelve months is 63.60% percent. Dynavax Technologies Corporation’s EBITDA margin for the year ended June 29 was 40.32%, whereas its operating margin stood at 19.80% for the same period. Based on annual data, it had gross profit of $460.53 million and revenue of $722.68 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DVAX’s return on assets (ROA) during the last 12 months has been 11.30%. There was a 35.20% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 19.90%.
Earnings Surprise
According to Dynavax Technologies Corporation’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $60.25 million, while revenues fell by -324.0% to $46.93 million. It was predicted that Dynavax Technologies Corporation’s quarterly earnings would be $0.03, but it ended up being -$0.09, beating the consensus by 133.30%. EBITDA was -$5.38 million for the quarter. At the end of Dynavax Technologies Corporation’s most recent quarter ended June 29, its liabilities totaled 359.23 million, while its total debt was $257.83 million. Equity owned by shareholders amounts to $128.8 million.
Technical Picture
Here’s a quick look at Dynavax Technologies Corporation’s (DVAX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 58.73%, suggesting the stock is Neutral, with a 16.55% historical volatility rate.
The stochastic %K and %D were 78.50% and 83.61% respectively, while the average true range (ATR) was 0.38. Based on the 14-day stochastic reading of 67.80%, the RSI (14) reading is 59.60%. On the 9-day MACD Oscillator, the stock is at 0.24, and the 14-day reading is at 0.31.
Analyst Ratings
In its analyst report released on September 27, 2022, JMP Securities began covering Dynavax Technologies Corporation (NASDAQ: DVAX). The stock was rated as a Mkt outperform by the brokerage firm. Analysts have assigned Dynavax Technologies Corporation (DVAX) an Buy rating. DVAX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is DVAX’s price target for the next 12 months?
The current consensus forecast for the stock is between $21.00 and $27.00, with a median target price of $25.00. In analyzing these forecasts, the average price target given by analysts for Dynavax Technologies Corporation (DVAX) is $24.50.
